Drug
Inca000585
Inca000585: highest development phase Phase 2, developed by Incyte. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCA000585 NCT07104565 | Phase 2 | Immune Thrombocytopenia |
Latest
No recent events.
Follow Inca000585 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.